Compare Citigroup Inc. (C) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs Revvity Inc — how do they compare? Citigroup Inc. trades at $134.57 (market cap $227.30B), while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: Citigroup Inc. is far larger — about 18.3× Revvity Inc's market cap, and Citigroup Inc. pays the higher dividend (1.8%). Which is the better fit depends on your goals.
| C | RVTY | |
|---|---|---|
Market Cap | $227.30B | $12.41B |
Sector | Financials | Technology |
52-Week High | $145.67 | $117.75 |
52-Week Low | $90.02 | $82.26 |
Dividend Yield | 1.8% | 0.25% |
Enterprise Value | — | $14.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.
The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
